A Phase 2 Randomized Double-blind Placebo-controlled Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Brief description of study
This is a phase 2, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the efficacy and safety of ALXN2050, an oral complement FD inhibitor, in adult participants with proliferative lupus nephritis (LN) or Immunoglobulin A Nephropathy (IgAN).
Clinical Study Identifier: s22-00142
ClinicalTrials.gov Identifier: NCT05097989
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
